Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $5.84.

A number of research firms have commented on ZNTL. Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 9th.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC acquired a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at about $41,000. State of Wyoming lifted its position in Zentalis Pharmaceuticals by 63.4% during the 2nd quarter. State of Wyoming now owns 73,797 shares of the company’s stock valued at $86,000 after purchasing an additional 28,621 shares during the period. Man Group plc lifted its position in Zentalis Pharmaceuticals by 302.3% during the 2nd quarter. Man Group plc now owns 406,344 shares of the company’s stock valued at $471,000 after purchasing an additional 305,328 shares during the period. BNP Paribas Financial Markets lifted its position in Zentalis Pharmaceuticals by 145.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 173,484 shares of the company’s stock valued at $201,000 after purchasing an additional 102,661 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at about $1,126,000.

Zentalis Pharmaceuticals Stock Up 2.0%

NASDAQ:ZNTL opened at $1.54 on Thursday. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $4.44. The firm has a market capitalization of $111.10 million, a PE ratio of -0.68 and a beta of 1.77. The firm has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.19. On average, research analysts expect that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.